Bayer invested 13.2 million euros in the Iberia region in 2017, 10% more than in the previous year. Of this figure, 12.4 million euros were allocated to Spain, representing the largest investment in the Spanish pharmaceutical sector for the last ten years.
The company has over 2,200 employees in its ten work centers in Spain and Portugal. These include the Berlimed plant in Alcalá de Henares and La Felguera in Asturias, two of the beneficiaries of the 2017 investments. Last year Alcalá de Henares saw the launch of two new production lines that increased its production capacity by 40%. As we reported in January, this year the company will also spend one million euros on the continued enlargement of its facilities.
The home of the aspirin
The La Felguera plant in Asturias is currently celebrating its 75th anniversary, which was marked last year by the receipt of an investment of four million euros that was dedicated, among others, to building a new, more efficient, responsible and sustainable office space. This plant, which has 150 employees, produces 100% of Bayer's acetylsalicylic acid, the active principle in aspirin, which is exported to seven production centers that manufacture the tablets in their different formats.
According to Rainer Krause, CEO of Bayer in the Iberia region: “Our commitment to innovation is transversal in all divisions. This year’s results show Bayer’s efforts to implement the innovative capacity of our teams in all its services and give us strength to face future challenges with optimism”.
The investment data have been published along with the results for 2017, and show that Bayer increased its sales in Iberia by 2.3%, with a total of 842 million euros. Specifically in Spain, the turnover was 678 million, up 1.7% from 2016.
Last updated: 13|04|2018